Pages that link to "Q37383462"
Jump to navigation
Jump to search
The following pages link to Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors (Q37383462):
Displaying 36 items.
- Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery (Q24188177) (← links)
- Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates (Q27026389) (← links)
- Sclerotherapy Of Esophageal Varices In Severe Hemophilia A Patient And High Titer Inhibitor--Case Report (Q33429529) (← links)
- Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. (Q35069871) (← links)
- Hemophilia care in India: a review and experience from a tertiary care centre in uttar pradesh. (Q35163225) (← links)
- Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014. (Q37185097) (← links)
- Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX (Q37835878) (← links)
- Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature (Q37845931) (← links)
- Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects (Q38038332) (← links)
- Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery (Q38044492) (← links)
- How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011. (Q38060224) (← links)
- Recombinant activated factor VII in clinical practice: a 2014 update (Q38228494) (← links)
- Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors (Q38527511) (← links)
- Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients (Q38546790) (← links)
- Optimising musculoskeletal care for patients with haemophilia (Q38672487) (← links)
- Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors (Q38682218) (← links)
- The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors (Q39420691) (← links)
- U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors (Q39675759) (← links)
- Hemophilic chronic synovitis: therapy of hemarthrosis using endovascular embolization of knee and elbow arteries (Q40074647) (← links)
- Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors (Q40539842) (← links)
- The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors (Q41210614) (← links)
- Room-Temperature-Stable Recombinant Activated Coagulation Factor VII Recombinant: Chemical and Microbiologic Stability Over 24 Hours During Continuous In Vitro Infusion (Q44489884) (← links)
- Port-A-Cath infection causes inhibitor recurrence after initial successful ITI. (Q44578616) (← links)
- Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization (Q45838031) (← links)
- Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa (Q45855177) (← links)
- Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen (Q45862378) (← links)
- Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela (Q45865332) (← links)
- Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A (Q45867897) (← links)
- Patient/caregiver perceived benefits and barriers to elective orthopedic surgery (EOS) in patients with congenital hemophilia with inhibitors (Q45875600) (← links)
- How I treat inhibitors in haemophilia. (Q45879927) (← links)
- Guidelines for the management of hemophilia (Q45880345) (← links)
- Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents (Q45886119) (← links)
- [Treatment of haemophilia in Austria] (Q86605519) (← links)
- Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis (Q89777133) (← links)
- Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: a cost analysis in Spain (Q90706488) (← links)
- Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors (Q90858007) (← links)